Table 1.
Study | Design | Population | Treatment Dose | Cardiotoxicity Outcomes | Conclusion |
---|---|---|---|---|---|
Toure et al., 2022 [57] | Retrospective observational study | 8604 (274 African American and 8330 White participants) | Doxorubicin (dose ranged from 400 mg/m2 to 700 mg/m2) | Congestive heart failure (CHF) was detected in 27.8% of White participants and 32.5% of African Americans. | Significant differences between African Americans and White patients in hazard of incident CHF and cumulative incidence of incident CHF. |
Collin et al., 2020 [58] | Prospective observational study | 8503 (3580 African American and 4923 non-Hispanic White (NHW) participants) | Not specified | Anthracyclines were associated with a greater hazard ratio in African Americans (HR, 1.45) than in White breast cancer survivors (HR, 0.86); data were not statistically significant. | Disparity in chemotherapy-induced cardiotoxicity between African American and White breast cancer survivors contributed to the racial disparity in overall survival between these groups. |
Troeschel et al., 2019 [28] | Retrospective observational study | 407,587 (36,458 NHW) and 43,562 African American) | Not specified | The 20-year cumulative incidence of CVD-related mortality was 13.3% in African American women and 8.9% in NHW. Higher hazard ratio of cardiovascular mortality in African American breast cancer survivors compared with White breast cancer survivors (HR = 2.73 for those less than 50 and 1.72 for those aged 55 to 68 years). |
CVD-related mortality was significantly higher among African American than NHW breast cancer survivors, especially the young. |
Berkman et al., 2014 [59] | Retrospective observational study | 67,514 (54,518 White and 6113 African American participants) | Not specified | Higher hazard ratio of cardiovascular mortality in African American t cancer survivors compared with White breast cancer survivors (HR = 14.99 for the age group 40–49, HR = 6.43 for the age group 50–59, and HR = 2.26 for the age group 60–69). | Cardiovascular mortality was significantly higher in African American breast cancer survivors, especially among the young. |
Braithwaite et al., 2009 [27] | Retrospective observational study | 1254 (416 African American and 838 White participants) | Not specified | All-cause mortality was 39.7% in African Americans vs. 33.3% in White patients. The association between hypertension and all-cause survival accounted for 30% of the racial disparity in this outcome. | Hypertension is an independent predictor of the disparity between African American and White breast cancer survivors in cardiovascular outcomes and survival. |
Hasan et al., 2004 [26] | Retrospective observational study | 499 (100 African Americans and 399 White patients) | The median of cumulative doxorubicin dose infused over 48 h is 374 mg/m2; the range is between 264 and 580 mg/m2 | Higher incidence of doxorubicin-induced cardiotoxicity (LVEF less than 45%) among African American patients (7%) compared to White patients (2.5%). | Doxorubicin-induced cardiotoxicity is more in African American than in White patients. |